Asia Pacific Cardiovascular Needle Market to Grow at a CAGR of 7.8% to reach US$ 31,968.6 thousands by 2028 Million from 2021 to 2028

The cardiovascular needle market in Asia Pacific is expected to grow from US$ 18.80 Million in 2021 to US$ 31.96 Million by 2028; it is estimated to grow at a CAGR of 7.8% from 2021 to 2028

.

Cardiovascular diseases (CVDs) are the disorders of heart and blood vessels, and the category includes cerebrovascular disease, coronary heart disease, rheumatic heart disease, and other conditions. Tobacco consumption, unhealthy diet, and physical inactivity, which increase the risk of heart attacks and strokes, are a few of the major lifestyle factors that lead to the CVDs. Other risk factors causing these diseases include hypertension, diabetes, and increased cholesterol levels. CVDs are among the top 10 causes of death. According to the World Health Organization (WHO), cardiovascular diseases are number one cause of the death. Cardiovascular diseases (CVDs) are likely to remain the largest cause of morbidity and mortality. Fat depositions around blood vessels that prevents blood from flowing to the heart or brain is a main cause of heart attack and stroke. Bleeding vessels or blood clots in brain are a few other causes of stroke. Thus, the significantly rising incidence of CVDs is contributing to the high demand for diagnostic and treatment cardiovascular devices, which is driving the cardiovascular needle market growth.

The outbreak has severely affected the medical tourism industry in Asia pacific and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure, restrictions imposed by hospitals to the suppliers, decreasing in demand of cardiovascular surgical instruments and others. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent the disease transmission. These restrictive measures are anticipated to impact the supply chain and the availability of medical devices in these countries. It has affected disposable incomes and has also resulted in unemployment. Furthermore, business strategies such as acquisitions, mergers, and partnerships are adversely affected by the imposition of complete lockdown. Such obstructions in business activities are projected to hamper the manufacturing and distribution of several cardiovascular surgical instruments. However, increasing vaccination across the region and availability of government reimbursement policies for various cardiovascular procedures is expected to normalize the situation in Asia Pacific region and will gradually increase the demand for cardiovascular needles.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the cardiovascular needle market. The Asia Pacific cardiovascular needle market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Cardiovascular Needle Market Segmentation          

By Application

• Open Heart Surgery
• Cardiac Valve Procedures

By Usage

• Single Use
• Multiple Uses

By End User

• Hospitals and Clinics
• Ambulatory Surgical Centres
• Cardiovascular Centres

By Country

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

Companies Mentioned

1. Ethicon (Johnson & Johnson Services, Inc.)    
2. MANI, INC         
3. Barber of Sheffield       
4. FSSB surgical needles GmbH    
5. Medtronic         
6. Teleflex Incorporated    
7. Meril Life Sciences Pvt. Ltd.      
8. CP Medical        
9. SMB Corporation of India
10. Aurolab

Asia Pacific Cardiovascular Needle Report Scope